1S9 Stock Overview
A microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Risk Analysis
+ 2 more risks
Seres Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.57 |
| 52 Week High | US$1.47 |
| 52 Week Low | US$0.52 |
| Beta | 2.05 |
| 11 Month Change | -24.31% |
| 3 Month Change | -25.30% |
| 1 Year Change | -38.67% |
| 33 Year Change | -92.70% |
| 5 Year Change | -84.59% |
| Change since IPO | -98.42% |
Recent News & Updates
Recent updates
Shareholder Returns
| 1S9 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -6.7% | -1.9% | -0.2% |
| 1Y | -38.7% | -17.2% | 7.8% |
Return vs Industry: 1S9 underperformed the German Biotechs industry which returned -17.7% over the past year.
Return vs Market: 1S9 underperformed the German Market which returned 7.9% over the past year.
Price Volatility
| 1S9 volatility | |
|---|---|
| 1S9 Average Weekly Movement | 14.8% |
| Biotechs Industry Average Movement | 6.3% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 11.1% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 1S9's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 1S9's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2010 | 233 | Eric Shaff | www.serestherapeutics.com |
Seres Therapeutics, Inc., a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state. The company’s lead product candidate is VOWST, an oral microbiome therapeutic that has completed Phase III clinical trial for the treatment of recurrent Clostridioides difficile infection.
Seres Therapeutics, Inc. Fundamentals Summary
| 1S9 fundamental statistics | |
|---|---|
| Market cap | €92.99m |
| Earnings (TTM) | -€64.60m |
| Revenue (TTM) | €119.23m |
0.9x
P/S Ratio-1.7x
P/E RatioIs 1S9 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 1S9 income statement (TTM) | |
|---|---|
| Revenue | US$126.33m |
| Cost of Revenue | US$103.07m |
| Gross Profit | US$23.26m |
| Other Expenses | US$91.71m |
| Earnings | -US$68.44m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.40 |
| Gross Margin | 18.41% |
| Net Profit Margin | -54.18% |
| Debt/Equity Ratio | 0% |
How did 1S9 perform over the long term?
See historical performance and comparison